Dr. Jen Gunter on Women's HRT: What Clinicians Should Tell Patients

Who Is Dr. Jen Gunter and Why Clinicians Should Pay Attention

Dr. Jen Gunter is a Canadian-American OB-GYN and pain medicine physician whose public platform reaches millions of patients before they ever walk into an exam room. Her New York Times column, bestselling books, and TED talks have made her a primary information source for women navigating perimenopause and menopause. Clinicians who understand her messaging can meet patients where they already are.

From Vagina Bible to Menopause Manifesto

Gunter first gained wide recognition with "The Vagina Bible" (2019), then published "The Menopause Manifesto" in 2021. The latter became a New York Times bestseller and a de facto patient education manual. She wrote that "menopause is not a disease, but that doesn't mean it doesn't cause suffering that deserves medical attention." That framing matters clinically: patients who arrive referencing Gunter tend to be informed, motivated, and looking for a physician willing to discuss HRT without dismissiveness 1.

A Physician-Advocate in the Misinformation Era

Her public battles against jade eggs, vaginal steaming, and unregulated supplement claims established her credibility before she turned her attention to menopause. For clinicians, the practical takeaway is that Gunter-informed patients expect evidence-based answers. They have likely already encountered the WHI controversy and want a nuanced explanation, not a blanket "hormones are dangerous" or "hormones fix everything" 2.

The WHI Misinterpretation That Shaped a Generation of Under-Treatment

When the Women's Health Initiative estrogen-plus-progestin arm was halted in 2002, HRT prescribing dropped by an estimated 70-80% within a few years. Gunter has repeatedly called this "one of the greatest public health failures of the modern era." The 2017 WHI cumulative 18-year follow-up found no increase in all-cause mortality among women who had been randomized to conjugated equine estrogens alone (hazard ratio 0.94, 95% CI 0.88 to 1.01) 3.

What the Original Headlines Got Wrong

The 2002 data showed a small absolute increase in breast cancer risk with combined estrogen-progestin therapy: 8 additional cases per 10,000 woman-years. Media coverage omitted that context. The estrogen-only arm, which enrolled hysterectomized women, actually showed a reduced breast cancer incidence (hazard ratio 0.77, 95% CI 0.62 to 0.95) over 13 years of cumulative follow-up 4.

The "Timing Hypothesis" Clinicians Must Explain

The WHI enrolled women with a mean age of 63.3 years, well past the menopausal transition window when most women experience symptoms. The 2022 NAMS position statement affirms that for symptomatic women who are younger than 60 or within 10 years of menopause onset, "the benefits of hormone therapy generally outweigh the risks" 5. Gunter frequently cites this guideline in public forums. The age at initiation is the single most important variable to communicate during counseling.

Reframing Risk at the Bedside

Clinicians can reframe absolute risk using comparisons patients understand. The excess breast cancer risk from combined HRT (approximately 1 additional case per 1,250 women per year) is comparable to the risk associated with consuming two alcoholic drinks daily or with obesity itself 5. Gunter uses this comparison regularly in interviews and has noted that "we don't tell women to avoid wine without informed consent, yet we withhold hormones on the basis of less risk."

What Gunter Tells Patients About Starting HRT

Gunter's public counseling framework rests on three pillars: symptom-driven initiation, FDA-approved formulations first, and transparent risk-benefit conversations. These align with both the NAMS 2022 position statement and the Endocrine Society's 2019 clinical practice guideline on menopause management 6.

Symptom-Driven, Not "Optimization"-Driven

Gunter has publicly criticized the trend of prescribing HRT for vague "optimization" purposes in asymptomatic women. Her position: treat vasomotor symptoms, genitourinary syndrome of menopause (GSM), and bone loss prevention in appropriate candidates. She does not endorse testosterone for "vitality" in the absence of hypoactive sexual desire disorder (HSDD), a stance supported by the 2019 global consensus position statement on testosterone therapy for women, which found insufficient evidence for non-sexual indications 7.

FDA-Approved Formulations Over Compounded "Bioidenticals"

Gunter consistently warns patients against compounded bioidentical hormone therapy (cBHT). She has written that "compounded hormones are not safer, not better studied, and not more natural than FDA-approved bioidentical options." The 2020 National Academies of Sciences report on cBHT concluded that these products lack the quality control, labeling accuracy, and safety monitoring of FDA-approved drugs 8. FDA-approved micronized progesterone (Prometrium) and 17-beta estradiol patches are themselves bioidentical, a point Gunter emphasizes to counter marketing that conflates "bioidentical" with "compounded."

Transdermal Estrogen as a Default

Gunter has expressed a preference for transdermal estradiol over oral formulations in many clinical scenarios. This aligns with data showing that transdermal delivery avoids first-pass hepatic metabolism, producing lower VTE risk. A nested case-control study within the UK GPRD found that transdermal estrogen was not associated with increased VTE risk (odds ratio 0.96, 95% CI 0.64 to 1.46), while oral estrogen carried an approximately twofold increase 9. For patients with obesity, migraine with aura, or elevated thrombotic risk, transdermal delivery offers a meaningful safety advantage.

Vaginal Estrogen: The Most Underused Treatment in Menopause Care

Gunter devotes significant public advocacy to vaginal estrogen therapy. GSM affects an estimated 50-70% of postmenopausal women, yet prescribing rates remain far below prevalence 10.

Systemic Absorption Is Minimal

Low-dose vaginal estradiol (10 mcg inserts, estradiol cream, or the estradiol ring) produces serum levels that remain within the postmenopausal range. The 2020 NAMS position statement on GSM confirmed that vaginal estrogen does not require concomitant progestogen for endometrial protection when used at recommended doses 11. Gunter has said that "telling a woman she can't use vaginal estrogen because she had breast cancer is often not supported by the data," referencing the American College of Obstetricians and Gynecologists Committee Opinion 659, which allows consideration of vaginal estrogen in breast cancer survivors when non-hormonal options fail 12.

Beyond Dryness: Recurrent UTI Prevention

Vaginal estrogen reduces recurrent UTI incidence. A Cochrane review found that vaginal estrogen significantly reduced the number of UTIs compared to placebo (RR 0.64, 95% CI 0.47 to 0.86) 13. Gunter highlights this in clinical talks, noting that many women are prescribed repeated antibiotic courses when topical estrogen could address the underlying mucosal atrophy.

What Gunter Says She Uses Personally

Gunter has publicly disclosed that she takes menopausal hormone therapy. In interviews and on social media, she has confirmed using HRT for her own menopause symptoms. She has not disclosed her specific formulation in full detail, and clinicians should note that a physician's personal regimen is not a prescription recommendation. What matters is the principle she models: a physician who evaluates her own risk factors, reviews the evidence, and makes an individualized decision. That is the same process she advocates for every patient.

Countering Celebrity Hormone Misinformation

Gunter has publicly challenged celebrities and influencers who promote unregulated hormone protocols, pellet therapy without evidence-based dosing, or claims that HRT reverses aging. Her approach gives clinicians a framework for similar conversations.

The Problem With "Hormone Optimization" Marketing

The term "hormone optimization" has no standardized clinical definition. Gunter has pointed out that clinics marketing testosterone pellets, DHEA, and growth hormone secretagogues to menopausal women often cite no randomized controlled trial data. The Endocrine Society's 2019 guideline explicitly recommends against DHEA for menopausal symptoms due to insufficient evidence 6.

How Clinicians Can Redirect the Conversation

When patients arrive requesting treatments promoted by influencers, Gunter's model is instructive. She does not dismiss concerns. She validates the symptom, then redirects to what the evidence supports. A patient asking about pellet therapy can be told that FDA-approved transdermal and oral formulations have far more safety and efficacy data, that pellet dosing produces supraphysiologic peaks that are difficult to reverse once implanted, and that NAMS does not recommend pellet therapy as a first-line option 5.

Building a Gunter-Aligned Counseling Script for Your Practice

Clinicians can adapt Gunter's public positions into a structured counseling framework. The following points map directly to guideline-supported recommendations.

Step 1: Normalize the Conversation

Many women wait years before mentioning vasomotor symptoms or GSM to their physician. Proactively screen for hot flashes, night sweats, vaginal dryness, dyspareunia, and sleep disruption at every well-woman visit after age 40. The Study of Women's Health Across the Nation (SWAN) found that the median duration of vasomotor symptoms is 7.4 years, and for women whose symptoms began in early perimenopause, the median was over 11 years 14.

Step 2: Individualize the Risk-Benefit Discussion

Use the patient's age, time since menopause, cardiovascular risk profile, breast cancer history, VTE history, and symptom severity to determine candidacy. The 2022 NAMS algorithm provides a decision tree that is straightforward to implement in practice 5. For women with a uterus, combine estrogen with micronized progesterone or a progestogen. For hysterectomized women, estrogen alone is appropriate.

Step 3: Set Expectations on Duration

Gunter has publicly pushed back against arbitrary time limits on HRT. The NAMS 2022 position states there is no mandatory duration limit and that continuation should be re-evaluated periodically based on the individual's risk-benefit profile 5. The old "five-year rule" has no basis in current evidence.

Step 4: Address Vaginal Estrogen Separately

Vaginal estrogen for GSM can be initiated, continued, or added regardless of systemic HRT status. It does not carry the same risk profile as systemic therapy and should be discussed as a distinct treatment decision 11.

When HRT Is Not Appropriate: Gunter's Nuance

Gunter does not advocate HRT for all women. She has been explicit that women with a history of estrogen-receptor-positive breast cancer, active liver disease, unexplained vaginal bleeding, or recent VTE/PE require individualized evaluation and may not be candidates for systemic therapy. The 2022 NAMS position statement lists these as contraindications requiring specialist consultation 5. Non-hormonal alternatives including fezolinetant (Veozah), which gained FDA approval in May 2023 as a neurokinin-3 receptor antagonist for vasomotor symptoms, offer options for these patients. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by 60.5% at week 12 compared to 42.6% for placebo 15.